EGFR and central nervous system cancer: In the present study, results from the IHC and IB analysis suggested that upon sustained release from the nanoformulation, DIM inhibited EGFR pathway activation in both SSTR2 and EGFR overexpressed rat glioma samples (Figure 7A–7C, Supplementary Figure 10).